Catch up on recent interviews with Jeremie Calais, M.D. MSc, Krishna Patel, M.D., Phillip Kuo, M.D. Ph.D, and more faculty from the Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2023 conference.
Whether it was strategies to address the workforce pipeline in nuclear medicine, emerging insights on positron emission tomography (PET) in the management of prostate cancer and new research on the imaging of clear cell renal cell carcinoma, we learned quite a bit during on-site interviews at the Society of Nuclear Imaging and Molecular Imaging (SNMMI) 2023 conference in Chicago. Review the slideshow below to check out some of our on-site interviews from the conference.
New Multicenter Study Shows Viability of AI Tool for Detecting Central PE on CT
September 22nd 2023The Pulmonary Embolism (PE) Triage and Notification (PETN) module with RapidAI’s RapidPE platform reportedly demonstrated over 90 percent sensitivity and specificity rates for detection of central PE on computed tomography (CT), according to multicenter study findings presented at the 9th Annual Pulmonary Embolism Symposium.
Emerging PET/CT Agent May Enhance Diagnosis for Smaller Lesions of Clear Cell Renal Cell Carcinoma
September 20th 2023For cT1 renal masses < 4 cm and renal masses < 2 cm, the PET/CT agent 89Zr-DFO-girentuximab had respective sensitivity rates of approximately 85 percent and 96.7 percent for diagnosing clear cell renal cell carcinoma, according to research recently presented at the European Association of Nuclear Medicine (EANM) 2023 Congress.
Emerging PSMA PET Agent May Offer Improved Detection of Prostate Cancer
September 7th 2023The PSMA PET agent 64Cu SAR-bisPSMA detected a higher number of prostate cancer lesions and had a significantly higher SUVmax and SUVmean than 68Ga PSMA-11 PET/CT, according to initial data from a prospective multisite study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.
2 Clarke Drive
Cranbury, NJ 08512